Cara Therapeutics, Inc. (CARA) Reports Positive Top-Line Data from Adaptive Phase 2/3 Trial of I.V. CR845
Marijuana Stocks, Finance, & InvestingMedical Marijuana June 27, 2018
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced positive top-line data from the adaptive Phase 2/3 trial of I.V. CR845 in patients undergoing abdominal surgeries. At the... Read more
BREAKING NEWS: Epidiolex, First Non-Synthetic Cannabis Drug, Approved
Health & FitnessMarijuana Laws, Regulations, & PoliticsMedical MarijuanaNational & Federal Marijuana NewsUS Marijuana News June 25, 2018
Big win today for GW Pharma. In a previous post, we discussed GW Pharmaceuticals, the leading developer of cannabis-based pharmaceuticals. Today, the FDA announced the approval of GW Pharmaceutical’s drug Epidiolex (cannabidiol), an oral solution for treatment of seizures associated with two rare forms of epilepsy, Lennox-Gastaut syndrome and... Read more
InMed Pharmaceuticals Announces the Closing of C$14.95 Million Bought Deal Financing including Full Exercise of Underwriter’s Over-Allotment Option
Marijuana Stocks, Finance, & InvestingMedical Marijuana June 21, 2018
InMed Pharmaceuticals Inc. (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has closed the “bought deal” financing originally announced on June 12, 2018, and that... Read more
InMed Pharmaceuticals announces increase in Bought Deal offering to $13 million
Marijuana Stocks, Finance, & InvestingMedical Marijuana June 12, 2018
InMed Pharmaceuticals Inc. (TSX:IN) is pleased to announce that it has entered into an amended letter of engagement with Eight Capital, under which Eight Capital has now agreed to purchase, as underwriter, 14,444,560 units of the Company, on a “bought deal” basis pursuant to the filing of a shelf prospectus... Read more
Medical Cannabis Leadership from Canopy Growth and Subsidiary Spectrum Cannabis
Marijuana Stocks, Finance, & InvestingMedical Marijuana June 12, 2018
Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) is pleased to provide the following updates on its medical cannabis program and to re-affirm its strong commitment to medical cannabis, the patients who depend on it, and the Healthcare Professionals who prescribe it. HISTORIC CLINICAL TRIAL MILESTONES Marking a major milestone for medical... Read more
